1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

Regulatory Problems Mount For Supplement Firm Following Recall

 
• By Malcolm Spicer

in addition to distributing supplements containing ED ingredients, MS Bionic was in violation of an extensive list of supplement GMP regulations. Meanwhile Absonutrix makes claims for its herbals and botanicals including "aids in the inhibition of colon cancer cell growth and survival."

Vintage inscription made by old typewriter, warning

MS Bionic Inc.'s recall in 2016 after FDA found erectile dysfunction drugs in products the California firm marketed as dietary supplements was just the tip of its problems, according to the agency's latest warning letters submitted to supplement firms.

The letters FDA posted Aug. 1 also include the Office of Regulatory Affairs' warning to Absonutrix LLC about making drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Germany Leading Enforcement Against Unsafe Supplements Sold In EU

 
• By Tom Gallen

Germany was more active than any other EU member in the second quarter in submitting notifications to the Commission regarding problematic food supplements.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By David Ridley

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

FDA RIF Delays Response On NPA NMN Petition

 
• By Malcolm Spicer

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 
• By Malcolm Spicer

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.